4.8 Article

The ACSL3-LPIAT1 signaling drives prostaglandin synthesis in non-small cell lung cancer

Journal

ONCOGENE
Volume 39, Issue 14, Pages 2948-2960

Publisher

SPRINGERNATURE
DOI: 10.1038/s41388-020-1196-5

Keywords

-

Funding

  1. Swiss National Science Foundation (SNSF) [PP00P3_163929]
  2. Novartis Foundation for medical-biological research [16C190]
  3. UniBern Forschungsstiftung
  4. SNSF [163359]
  5. Swiss National Science Foundation (SNF) [PP00P3_163929] Funding Source: Swiss National Science Foundation (SNF)

Ask authors/readers for more resources

Enhanced prostaglandin production promotes the development and progression of cancer. Prostaglandins are generated from arachidonic acid (AA) by the action of cyclooxygenase (COX) isoenzymes. However, how cancer cells are able to maintain an elevated supply of AA for prostaglandin production remains unclear. Here, by using lung cancer cell lines and clinically relevant Kras(G12D)-driven mouse models, we show that the long-chain acyl-CoA synthetase (ACSL3) channels AA into phosphatidylinositols to provide the lysophosphatidylinositol-acyltransferase 1 (LPIAT1) with a pool of AA to sustain high prostaglandin synthesis. LPIAT1 knockdown suppresses proliferation and anchorage-independent growth of lung cancer cell lines, and hinders in vivo tumorigenesis. In primary human lung tumors, the expression of LPIAT1 is elevated compared with healthy tissue, and predicts poor patient survival. This study uncovers the ACSL3-LPIAT1 axis as a requirement for the sustained prostaglandin synthesis in lung cancer with potential therapeutic value.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available